SEC 13F Intelligence

Managers / Q3 2022 · view latest →

ORBIMED ADVISORS LLC

CIK 0001055951 · 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK, NY, 10022 · (212) 739-6400

Reported Value
$5.4B
Q3 2022
Positions
132
Filings on Record
30
2019–present window
Filed
Nov 14, 2022
original filing

Summary

Orbimed Advisors Llc reported $5.4B in U.S.-listed holdings across 132 positions for Q3 2022.

Its largest position, Sinovac Biotech, represents 6.3% of the portfolio.

Compared with Q2 2022, the fund opened 14 new positions and exited 24.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $5.4BQ4 ’18Q1 ’19: $6.5BQ2 ’19: $6.5BQ3 ’19: $5.3BQ4 ’19: $7.0BQ4 ’19Q1 ’20: $6.0BQ2 ’20: $7.1BQ3 ’20: $8.0BQ4 ’20: $11.4BQ4 ’20Q1 ’21: $10.7BQ2 ’21: $9.9BQ3 ’21: $9.1BQ4 ’21: $7.8BQ4 ’21Q1 ’22: $6.2BQ2 ’22: $5.5BQ3 ’22: $5.4BQ4 ’22: $5.23TQ4 ’22Q1 ’23: $5.1BQ2 ’23: $5.5BQ3 ’23: $4.7BQ4 ’23: $5.0BQ4 ’23Q1 ’24: $5.5BQ2 ’24: $5.1BQ3 ’24: $5.5BQ4 ’24: $4.9BQ4 ’24Q1 ’25: $4.2BQ2 ’25: $4.0BQ3 ’25: $4.3BQ4 ’25: $4.9BQ4 ’25Q1 ’26: $5.0Bfilingsflow.com

Portfolio Composition

By security type

Composition data arrives with ticker enrichment.

Quarter-over-Quarter Changes full breakdown →

Holdings — Q3 2022

Loading…
Export to Excel
#IssuerClass% PortfolioValue ↓Shares

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$5.0B114May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$4.9B108Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$4.3B110Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$4.0B103Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$4.2B111May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$4.9B119Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$5.5B119Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$5.1B115Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$5.5B115May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$5.0B111Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$4.7B128Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$5.5B127Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$5.1B125May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$5.23T116Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$5.4B132Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$5.5B145Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$6.2B145May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$7.8B159Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$9.1B173Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$9.9B160Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$10.7B159May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$11.4B149Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$8.0B143Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$7.1B135Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$6.0B142May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$7.0B136Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$5.3B116Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$6.5B128Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$6.5B124May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$5.4B131Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • ORBIMED CAPITAL LLC028-10410

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.